

350

METHODS OF TREATING METABOLIC SYNDROME USING
DOPAMINE RECEPTOR AGONISTS

ABSTRACT OF THE DISCLOSURE

355

The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, and insulin resistance (with or without treating obesity), associated with Metabolic Syndrome, comprising the step of administering to a patient suffering from Metabolic Syndrome a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine,

360

optionally combined with a pharmaceutically acceptable carrier.

\\15546\8\44291.1

365